Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients

Pazopanib is an angiostatic tyrosine kinase inhibitor (TKI) presently used for cancer treatment, particularly in patients with renal cell carcinoma (RCC). This treatment can be accompanied by mild bleeding as an adverse effect. Given the role of protein tyrosine kinases in platelet activation proces...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Cardiovasc Med
Main Authors: Tullemans, Bibian M. E., Nagy, Magdolna, Sabrkhany, Siamack, Griffioen, Arjan W., oude Egbrink, Mirjam G. A., Aarts, Maureen, Heemskerk, Johan W. M., Kuijpers, Marijke J. E.
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2018
Assuntos:
Cardiovascular Medicine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6232667/
https://ncbi.nlm.nih.gov/pubmed/30460241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcvm.2018.00142
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados